Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Matthew ShieldsEVP, Global Operations | Teva Pharmaceutical IndustriesTEVA | Open-market sale | 06/18 | 06/22 | 9,989 sh | $32.19 | $321,545.91 | −100.0% |
Kalif Eliyahu SharonEVP, CFO | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 06/11 | 06/16 | 106,563 sh | $34.10 | $3,633,798.3 | −61.9% |
Francis Richard D.President and CEO | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 06/05 | 06/08 | 6,153 sh | $34.35 | $211,355.55 | −0.5% |
Matthew ShieldsEVP, Global Operations | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 06/03 | 06/04 | 16,195 sh | $32.87 | $532,329.65 | −61.9% |
Kalif Eliyahu SharonEVP, CFO | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 05/14 | 05/18 | 153,251 sh | $35.61 | $5,457,268.11 | −47.1% |
Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 05/14 | 05/18 | 41,658 sh2 trades | $35.58avg. | $1,482,191.64 | −48.5% | |
Amir WeissChief Accounting Officer | Teva Pharmaceutical IndustriesTEVA | Open-market sale | 05/06 | 05/07 | 10,679 sh | $36.00 | $384,444 | −34.8% |
Daniell RichardEVP, Europe Commercial | Teva Pharmaceutical IndustriesTEVA | Open-market sale | 05/05 | 05/07 | 30,000 sh | $35.40 | $1,062,000 | −35.0% |
Sabag MarkSee "Remarks" | Teva Pharmaceutical IndustriesTEVA | Open-market sale | 05/01 | 05/04 | 144,180 sh | $34.99 | $5,044,858.2 | −64.1% |
Fox ChristineEVP, U.S. Commercial | Teva Pharmaceutical IndustriesTEVA | Open-market sale | 04/30 | 05/04 | 21,258 sh | $35.31 | $750,619.98 | −25.0% |
Sabag MarkSee "Remarks" | Teva Pharmaceutical IndustriesTEVA | Open-market sale | 03/17 | 03/19 | 62,102 sh | $30.14 | $1,871,754.28 | −21.6% |
Francis Richard D.President and CEO | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 03/05 | 03/09 | 20,025 sh | $31.67 | $634,191.75 | −1.7% |
Daniell RichardEVP, Europe Commercial | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 03/05 | 03/09 | 17,295 sh | $31.67 | $547,732.65 | −16.8% |
Hughes Eric A.See "Remarks" | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 03/05 | 03/09 | 9,533 sh | $31.67 | $301,910.11 | −8.1% |
Fox ChristineEVP, U.S. Commercial | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 03/05 | 03/09 | 7,924 sh | $31.67 | $250,953.08 | −8.5% |
Matthew ShieldsEVP, Global Operations | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 03/05 | 03/09 | 17,295 sh | $31.67 | $547,732.65 | −63.4% |
Placid JoverSee "Remarks" | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 03/05 | 03/09 | 14,150 sh | $31.67 | $448,130.5 | −67.6% |
Brian SavageInterim Chief Legal Officer | Teva Pharmaceutical IndustriesTEVA | Open-market sale | 03/05 | 03/09 | 1,127 sh | $31.67 | $35,692.09 | −9.4% |
Francis Richard D.President and CEO | Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 03/04 | 03/06 | 23,393 sh | $32.46 | $759,336.78 | −2.0% |
Teva Pharmaceutical IndustriesTEVA | Open-market sale10b5-1 plan | 03/04 | 03/06 | 91,345 sh3 trades | $32.66avg. | $2,983,370.98 | −51.6% |